The Psoriasis Pipeline
Dr. Andrew Blauvelt discusses new possibilities in the psoriasis treatment pipeline, from an investigational biologic with unprecedented efficacy, to promising new oral TYK2 options and new strategies for oral drug delivery. Andrew Blauvelt, MD, MBA, Dermatologist, Portland, Oregon, and Investigator, Oregon Medical Research Center “I’m excited about the psoriasis pipeline. It’s different than in the past. […]